

# BISPHOSPHONATES

## KEY POINTS

- Oral bisphosphonates are effective in the prevention of secondary fractures with one fracture avoided for every 40–90 patients treated for 1–3 years.
- Many patients who have had 5 years of continuous treatment with an oral bisphosphonate will have ongoing benefit for a further 5 years after cessation of the bisphosphonate.
- Where ongoing treatment for osteoporosis is required, options other than bisphosphonates may be safer.

## CONTEXT

This guide considers the deprescribing of oral bisphosphonates in the treatment of osteoporosis.

## RECOMMENDED DEPRESCRIBING STRATEGY

- 1 Patients with a history of osteoporosis who have had 5 years of bisphosphonate treatment and whose risk of fracture is now low should have their bisphosphonate ceased for 5 years.
- 2 A plan for regular (eg. biennial) monitoring of bone mineral density may be of benefit to monitor for any decline.
- 3 Bisphosphonates can usually be ceased without the need for tapering.

## EFFICACY

A recent systematic review of 315 studies looked at the effectiveness and adverse events of a range of treatments to prevent fractures.<sup>1</sup> Their findings indicate strong evidence for the efficacy of a number of bisphosphonates. The magnitude of the effect indicated a NNT of between 40 and 89 over 1–3 years of treatment to prevent one fracture in women.<sup>1</sup>

The FLEX trial looked at the legacy effect of alendronate for patients who had been treated in the FIT trial for 5 years.<sup>2</sup> They found that there was no difference in non-vertebral fracture risk in patients who continued alendronate for a further 5 years, compared to those that took a placebo for the five years. There was however an increase in the number of clinical vertebral fractures in patients who took placebo instead of alendronate (23/437; 5.3%) vs 16/662; 2.4% respectively; NNT 34 for one vertebral fracture over 5 years.

The same authors reanalysed the data at a later date to look more closely at those patients with nonvertebral fractures.<sup>3</sup> They clarified that in those patients without a previous vertebral fracture and a T score of -2.5 or less (when they had completed 5 years of alendronate treatment) that there was a benefit in fracture risk reduction (14.7% vs 28%, NNT ~7 over 5 years) compared to no benefit in those patients with a T score of -2.5 or above.<sup>3</sup>

## ADVERSE EFFECTS

Bisphosphonates are poorly absorbed (less than 5% bioavailable) and as such require relatively strict administration procedures. It is recommended that patients do not lie down for 30min after taking the agent and that it be taken at least an hour before the first food or beverage of the day.

## &lt; ADVERSE EFFECTS continued from page 1

They are highly irritant to the oesophageal mucosa and can cause a range of upper abdominal and gastrointestinal symptoms (abdominal pain ~ 7%, acid dyspepsia, regurgitation and nausea (all ~ 4%).<sup>4</sup>

Long term use has been associated with an increased risk of atypical fractures. A report of a Nationwide study of bisphosphonate use in Sweden indicated a markedly increased relative risk of fracture of the femoral shaft in both women (RR 55; 95% CI 39-79) and men (RR 54; 95% CI 15-192). The risk increases with duration of use.<sup>5</sup> The absolute risk remained low (11 per 10,000 years of patient use; NNH 909) and the risk decreased rapidly (by 70% per year) after cessation of bisphosphonate.

Bisphosphonate associated osteonecrosis of the jaw (ONJ) is a rare, but serious clinical condition caused by anti-osteoclastic, antiangiogenic and anti-human endothelial cell proliferation effects of bisphosphonates, which inhibit bone turnover.<sup>6</sup> ONJ more often develops in those patients who are receiving either long term nitrogen containing IV bisphosphonate therapy alone or have associated invasive dental procedures.<sup>6</sup> Incidence is difficult to ascertain with one of the major drug companies estimating an incidence rate of 0.7 per 100,000 patients (0.0007%) for oral therapy.<sup>7</sup> Estimates of 0.001% to 0.01% have been proposed by other authors (NNH of 1000-10,000).<sup>8, 9, 10, 11</sup>

## RESOURCES

- ☒ QUICK REFERENCE GUIDE
- ☒ ANTIHYPERTENSIVES GUIDE
- ☒ ANTIPLATELET AGENTS GUIDE
- ☒ ANTIPSYCHOTICS GUIDE
- ☒ BENZODIAZEPINES GUIDE
- ☒ BISPHOSPHONATES GUIDE
- ☒ STATINS GUIDE
- ☒ VITAMIN D & CALCIUM GUIDE



[www.consultantpharmacyservices.com.au](http://www.consultantpharmacyservices.com.au)



[www.primaryhealthtas.com.au](http://www.primaryhealthtas.com.au)



## FACTORS TO CONSIDER BEFORE DEPRESCRIBING

## IN FAVOUR OF DEPRESCRIBING

## LOW RISK OF FALLS/IMMOBILITY

- ✔ If patients have a low risk of falls, there may no longer be ongoing benefit to fracture risk reduction. Indeed if the reduced falls risk is due to prolonged immobility, even the requirement to sit upright to administer the oral bisphosphonate may be sufficient reason to reconsider the therapy.

## NO PREVIOUS VERTEBRAL FRACTURES AND 5 YEARS OR MORE OF TREATMENT

- ✔ In patient with only non-vertebral fractures, there seems to be little ongoing benefit of bisphosphonates in the 5 years after an initial 5 years of treatment, particularly if their T score is above -2.5 at the end of the first 5 years.

## AGAINST DEPRESCRIBING

## HIGH FRACTURE RISK

- ✖ Patients with a higher risk of fractures such as those with a very low T score (-2.5 or below) may have ongoing benefit of fracture risk reduction from treatment with a bisphosphonate or another antiresorption agent.



## DISCONTINUATION SYNDROMES

None.

## REFERENCES

1. Crandall CJ et al. Comparative effectiveness of pharmacological treatments to prevent fractures. *Ann Intern Med* 2014; 161: 711-723.
2. Dennis M, Black et al. Effects of Continuing or Stopping Alendronate After 5 Years of Treatment The Fracture Intervention Trial Long-term Extension (FLEX): A Randomized Trial. *JAMA*. December 27, 2006—Vol 296, No. 24.
3. Ann V Schwartz et al. Efficacy of Continued Alendronate for Fractures in Women With and Without Prevalent Vertebral Fracture: The FLEX Trial. *Journal of Bone and Mineral Research*, Vol. 25, No. 5, May 2010, pp 976-982.
4. UpToDate. Lexicomp Drug information, Copyright 1978-2015 Lexicomp.
5. Jörg Schilcher et al. Risk of atypical femoral fracture during and after bisphosphonate use; Full report of a nationwide study. *Acta Orthopaedica* 2015; 86 (1): 100-107.
6. Kumar V et al. Nitrogen containing bisphosphonates associated osteonecrosis of the jaws: A review for past 10 year literature. *Dental Research Journal* 2014 11(2) 147-153.
7. Paiva-Fonseca F, Santos-Silva AR, Della-Coletta R, Vargas PA, Lopes MA. Alendronate-associated osteonecrosis of the jaws: A review of the main topics. *Med Oral Patol Oral Cir Bucal*. 2014 Mar 1;19 (2):e106-11.
8. Malden N, Lopes V. An epidemiological study of alendronate-related osteonecrosis of the jaws. A case series from the south-east of Scotland with attention given to case definition and prevalence. *J Bone Miner Metab*. 2012;30:171-82.
9. Sedghizadeh PP, Stanley K, Caligiuri M, Hofkes S, Lowry B, Shuler CF. Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: An institutional inquiry. *J Am Dental Assoc*. 2009;140:61-6.
10. Manfredi M, Merigo E, Guidotti R, Meleti M, Vescovi P. Bisphosphonate-related osteonecrosis of the jaws: a case series of 25 patients affected by osteoporosis. *Int J Oral Maxillofac Surg*. 2011;40:277-84.
11. Lo JC, O'Ryan FS, Gordon NP, Yang J, Hui RL, Martin D, et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. *J Oral Maxillofac Surg*. 2010;68:243-53.